Skip to main content

Table 1 Patient baseline characteristics

From: Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US

Baseline characteristicsa

Patients with multiple metastases

Patients with a single metastasis

P-value†

N = 291

N = 408

Age at BC diagnosis, median years (range)

61.0 (35.0, 83.0)

61.0 (33.0, 90.0)

0.785

Age at index treatment initiation, median years (range)

65.0 (38.0, 86.0)

64.0 (33.0, 91.0)

0.878

Menopausal status at the first BC diagnosisb, n (%)

 Postmenopausal

169 (58.1)

238 (58.3)

0.946

Race, n (%)

  

 White

155 (53.3)

254 (62.3)

0.017*

 Non-white

136 (46.7)

154 (37.7)

Insurance plan type at mBC diagnosis, n (%)

  

 Commercial/private insurance

151 (51.9)

217 (53.2)

0.460

 Medicare only

115 (39.5)

166 (40.7)

 Others

25 (8.6)

25 (6.1)

Type of index treatment, n (%)

  

 Endocrine therapyc

196 (67.4)

356 (87.3)

<0.001*

 Chemotherapyd

95 (32.6)

52 (12.7)

Line of index treatment, n (%)

 First line

81 (27.8)

206 (50.5)

<0.001*

 Second line

97 (33.3)

97 (23.8)

 Third line and above

113 (38.8)

105 (25.7)

mBC type, n (%)

  

 Recurrent patients with adjuvant endocrine therapy

184 (63.2)

290 (71.1)

0.033*

 Recurrent patients without adjuvant endocrine therapy

39 (13.4)

54 (13.2)

 De novo

68 (23.4)

64 (15.7)

Number of non-lymph-node metastatic sites at mBC diagnosis, n (%)

  

 1

58 (19.9)

228 (55.9)

<0.001*

 2

75 (25.8)

132 (32.4)

 3

132 (45.4)

8 (2.0)

 4

20 (6.9)

2 (0.5)

Sites of metastatic disease at mBC diagnosis, n (%)

  

 Bone

188 (64.6)

231 (56.6)

0.034*

 Liver

110 (37.8)

53 (13.0)

<0.001*

 Lung

151 (51.9)

90 (22.1)

<0.001*

 Any visceral metastasese

228 (78.4)

143 (35.0)

<0.001*

 Brain

3 (1.0)

2 (0.5)

0.654

 Other

4 (1.4)

5 (1.2)

1.000

Number of non-lymph-node metastatic sites at index treatment initiation, n (%)

 1

0 (0.0)

374 (91.7)

<0.001*

 2

208 (71.5)

0 (0.0)

 3

79 (27.1)

0 (0.0)

 4

4 (1.4)

0 (0.0)

Sites of metastatic disease at index treatment initiation, n (%)

 Bone

224 (77.0)

231 (56.6)

<0.001*

 Liver

177 (60.8)

47 (11.5)

<0.001*

 Lung

215 (73.9)

87 (21.3)

<0.001*

 Any visceral metastasese

288 (99.0)

139 (34.1)

<0.001*

 Brain

10 (3.4)

2 (0.5)

0.005*

 Other

6 (2.1)

2 (0.5)

0.073

Adjusted Charlson Comorbidity Index (CCI)f at index treatment initiation, median (range)

0.0 (0.0, 8.0)

0.0 (0.0, 6.0)

0.002*

ECOG performance status at index treatment initiation, n (%)

 0

49 (16.8)

134 (32.8)

<0.001*

 1

151 (51.9)

164 (40.2)

 2

45 (15.5)

24 (5.9)

 3

8 (2.7)

2 (0.5)

 Not recorded in medical record

38 (13.1)

84 (20.6)

Use of chemotherapy for mBC before index treatment initiation, n (%)

66 (22.7)

42 (10.3)

<0.001*

Duration from initiation of last adjuvant endocrine therapy to mBC diagnosis, median months (range)

19.2 (0.0, 216.6)

18.9 (0.0, 130.8)

0.879

Duration from initiation of index treatment to available follow-up, median months (range)

16.3 (1.0, 25.2)

16.7 (1.0, 24.6)

0.239

  1. BC breast cancer, ECOG Eastern Cooperative Oncology Group, mBC metastatic breast cancer
  2. * p < 0.05
  3. † Statistical comparisons were conducted using Wilcoxon rank-sum tests for continuous variables and Chi square tests for categorical variables
  4. aDisease characteristics described at new treatment initiation include age, treatment type, line of index treatment, number and sites of metastases, adjusted CCI, ECOG performance status, and prior chemotherapy for mBC. Menopausal status, race, insurance plan type, mBC type, number and sites of metastases, and time elapsed (months) from initiation of last adjuvant endocrine therapy to stage IV mBC diagnosis were assessed at mBC diagnosis. Duration from initiation of index treatment to available follow-up was assessed at the end of follow-up
  5. bThe exact variable for menopausal status was not collected in the study but instead imputed based on age (postmenopausal: age ≥60)
  6. cEndocrine therapy includes endocrine monotherapy (anastrozole, exemestane, fluoxymesterone, fulvestrant, letrozole, megestrol acetate, tamoxifen), combination therapy with two endocrine agents (fulvestrant + anastrozole, fulvestrant + exemestane, fulvestrant + exemestane, fulvestrant + tamoxifen), and everolimus-based therapies (everolimus, everolimus + anastrozole, everolimus + exemestane, everolimus + fulvestrant, everolimus + letrozole)
  7. dChemotherapy includes chemotherapy monotherapy (capecitabine, docetaxel, gemcitabine, ixabepilone, paclitaxel, protein-bound paclitaxel, vinorelbine), combinational therapy of two chemotherapy agents (cyclophosphamide + docetaxel, cyclophosphamide + doxorubicin, doxorubicin + docetaxel, paclitaxel + gemcitabine), and combinational therapy of chemotherapy and endocrine therapy (anastrozole + paclitaxel, fulvestrant + capecitabine, fulvestrant + paclitaxel, letrozole + paclitaxel)
  8. eAny visceral metastases refer to liver, lung, and other visceral metastases, including peritoneum, adrenal gland, and kidney
  9. fThe adjusted CCI calculates the comorbidity index excluding metastatic breast cancer (score of 6)
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us